Shares of Amarin Corporation (AMRN) have risen by 20% since my initial article on the company back in May, in which I told readers to expect a run up shortly. While shares did increase by almost half at one point, the stock has come back down although it remains in an uptrend.
AMRN data by YCharts
Keys to the original bullish thesis included the following:
Prescription growth for the company’s primary asset, Vascepa, had grown 50% every quarter for the past three quarters. Management projected $155 million to $165 million in 2017 revenue, while weekly scripts continued to power higher with market share at an all time high. Tailwinds from managed care coverage continued to aid the company’s efforts after several plans put Vascepa on exclusively and removed Lovaza. Prior data was promising and suggestive of cardio-protective benefits while lowering triglyceride levels without increasing LDL-C levels. The ongoing REDUCE-IT study is the first cardiovascular outcomes study to test Vascepa in a high-risk statin treated population, with 8,175 patients randomized to receive the study drug or placebo. The primary endpoint is time to first occurrence of composite MACE and under special protocol assessment for 90% power to detect a 15% relative risk reduction. I suggested that shares would run up into the pre-specified interim efficacy and safety analysis by the independent DMC, as well as into the middle of next year into top-line results.
In mid-August the company announced that the interim review by the independent data monitoring committee was completed, with the recommendation that the study continue as planned without being modified. Although Wall Street was obviously disappointed that early stoppage didn’t take place, management reminded investors that the bars for stopping the study were quite high as the desire was to obtain a more robust result by seeing the trial through to completion. They again guided data to be released in the second or third quarter of 2018. As a reminder, the interim analysis occurred after 80% of the target 1,612 primary cardiovascular events occurred and final efficacy analysis will take place after 100% of events. Keep in mind the company itself is blinded to both interim data and results until after the study is stopped (when database is locked at final analysis).
day trading penny stocks: Cheniere Energy Partners, LP(CQP)
- [By Maxx Chatsko]
While numerous LNG export terminals dotting the Gulf Coast are in various stages of development, the first major facility and current largest producer is the Sabine Pass facility owned by Cheniere Energy Partners LP (NYSEMKT:CQP). The partnership is largely controlled and majority-owned by Cheniere Energy. That means the current 6.9% distribution yield is essentially funding the construction of the parent’s next export facility in Corpus Christi, although any investor seeking income can get in on the action.
day trading penny stocks: China Automotive Systems, Inc.(CAAS)
- [By Monica Gerson]
China Automotive Systems, Inc. (NASDAQ: CAAS) is projected to post its quarterly earnings at $0.20 per share on revenue of $108.22 million.
Affimed NV (NASDAQ: AFMD) is projected to post a quarterly loss at $0.18 per share on revenue of $1.71 million.
- [By Joseph Griffin]
TRADEMARK VIOLATION WARNING: “Brokerages Expect China Automotive Systems (CAAS) to Post $0.18 Earnings Per Share” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at www.tickerreport.com/banking-finance/3349149/brokerages-expect-china-automotive-systems-caas-to-post-0-18-earnings-per-share.html.
day trading penny stocks: Kering S.A. (PPRUF)
- [By SEEKINGALPHA.COM]
Kering Group (OTC:PPRUF), which operates the Gucci and YSL brands, said on February 10 that 2016 saw a same-store sales increase of 11 percent in Asia ex-Japan, which was mostly led by a rebound in China. LVMH, which owns brands such as Louis Vuitton, Bulgari, and Hennessy, also highlighted positive momentum going forward in its fourth-quarter earnings call with investors. Hugo Boss Group’s mainland China same-store sales also increased close to 20 percent during 2016, adjusted for currency.
day trading penny stocks: FuelCell Energy Inc.(FCEL)
- [By Peter Graham]
A long term performance chart shows Ballard Power Systemsalong with alternative energy or fuel cell stock peers like small capsFuelCell Energy Inc (NASDAQ: FCEL), Hydrogenics Corporation (NASDAQ: HYGS) and Plug Power Inc (NASDAQ: PLUG) all peaking in 2014 before falling back; but BLDP and PLUG have picked up steam earlier this year:
- [By Peter Graham]
A long term performance chart shows shares of Plug Power along withalternative energy or fuel cell stock peers like Ballard Power Systems Inc (NASDAQ: BLDP), FuelCell Energy Inc (NASDAQ: FCEL) and Hydrogenics Corporation (NASDAQ: HYGS) all peaking in 2014 with shares leveling off or just sliding downward moderately over the past year:
- [By Lisa Levin]
FuelCell Energy Inc (NASDAQ: FCEL) shares dropped 33 percent to $1.08. FuelCell Energy priced its $15.4 million underwritten public offering of common stock and warrants.
- [By Peter Graham]
The Q4 2016 earnings report for small cap fuel cell stockFuelCell Energy Inc (NASDAQ: FCEL) is scheduled forbefore the marketopens onThursday (January 12th). At the beginning of December, FuelCell Energy announced a business restructuring to reduce costs and align production levels with current levels of demand in a manner that is consistent with the Companys long-term strategic plan.The Company said it cut 96 jobs, or 17% of its workforce, and has halved production to 25 megawatts a year in order to position for delays in order flow.The Company alsoexpects to take a $3 million charge in fiscal 2017 related to the job cuts.
day trading penny stocks: Neuralstem, Inc.(CUR)
- [By Lisa Levin]
Shares of Neuralstem, Inc. (NYSE: CUR) were down 29 percent to $1.75. Neuralstem reported the pricing of public offering of common stock and warrants.
- [By William Romov]
Last Wednesday (Dec. 6), the company received a patent for certain methods of production of its phase 2 antidepressant, AV-101.
Penny Stock Current Share Price Dec. 4 – Dec. 8 Gain (as of Dec. 8)
VistaGen Therapeutics Inc. (Nasdaq: VTGN) $1.80 135%
FXCM Inc. (Nasdaq: GLBR) $1.12 124%
Neuralstem Inc. (Nasdaq: CUR) $2.00 75.44%
Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.49 75.29%
ClearSign Combustion Corp. (Nasdaq: CLIR) $3.50 53.85%
Astrotech Corp. (Nasdaq: ASTC) $4.21 51.99%
Burcon NutraScience Corp. (Nasdaq: BUR) $0.72 44%
LM Funding America Inc. (Nasdaq: LMFA) $3.72 42.53%
Second Sight Medical Products Inc. (Nasdaq: EYES) $1.75 42.28%
Globus Maritime Ltd. (Nasdaq: GLBS) $1.47 41.35%
As a result, its share price shot up from $0.92 to $2.52 on Wednesday. The stock pulled back to $1.80 by the end of the week, for a total gain of 135% for the week.